Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICN Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Amy Feller who wrote (936)	10/29/1998 11:21:00 PM
From: Clouseau	Read Replies (2) \| Respond to of 1029

Folks - I've taken the liberty to cut/paste Jim Frankel's Yahoo post giving an initial assessment of the WDR report in ICN...good summary of the upside potential. ----------------------- Some points made: 1. Undervalued compared to peers 2. Rebetron's Blockbuster potential 3. ICN leading push into Eastern Europe and Russia. 4. $200 million debt offering in August 98 may fuel more accretive acquisitions. 5. Yugo's inportance decreasing rapidly. 6. Improved, centralized accounting standards. 7. Best positioned pharmaceutical company in Eastern Europe and Russia. 8. Stong experienced managment team. 9. ICN's human resource inventory an enormous, as yet untapped, competitive advantage. Whether it's a $200 per month Ph.D. (actually, now less tha $100 per month after devaluation) ... 10. An attractive acquisition candidate. Lots more goodies. ----------------- Discussion? Dave